TY  - GEN
AU  - Fountzilas,George
AU  - Giannoulatou,Eleni
AU  - Alexopoulou,Zoi
AU  - Zagouri,Flora
AU  - Timotheadou,Eleni
AU  - Papadopoulou,Kyriaki
AU  - Lakis,Sotiris
AU  - Bobos,Mattheos
AU  - Poulios,Christos
AU  - Sotiropoulou,Maria
AU  - Lyberopoulou,Aggeliki
AU  - Gogas,Helen
AU  - Pentheroudakis,George
AU  - Pectasides,Dimitrios
AU  - Koutras,Angelos
AU  - Christodoulou,Christos
AU  - Papandreou,Christos
AU  - Samantas,Epaminontas
AU  - Papakostas,Pavlos
AU  - Kosmidis,Paris
AU  - Bafaloukos,Dimitrios
AU  - Karanikiotis,Charisios
AU  - Dimopoulos,Meletios-Athanassios
AU  - Kotoula,Vassiliki
TI  - TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
SN  - 1949-2553
PY  - 2017///1226
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Immunological
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Chemotherapy, Adjuvant
KW  - Chi-Square Distribution
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - Clinical Trials as Topic
KW  - DNA Mutational Analysis
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Female
KW  - Genetic Predisposition to Disease
KW  - Greece
KW  - Humans
KW  - Immunohistochemistry
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Mutation
KW  - Patient Selection
KW  - Phenotype
KW  - Predictive Value of Tests
KW  - Proportional Hazards Models
KW  - Prospective Studies
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Time Factors
KW  - Trastuzumab
KW  - Treatment Outcome
KW  - Triple Negative Breast Neoplasms
KW  - chemistry
KW  - Tumor Suppressor Protein p53
KW  - Young Adult
N1  - Publication Type: Journal Article; Multicenter Study
UR  - https://doi.org/10.18632/oncotarget.9022
ER  -